Cooley Advised TriGemX Bio on Business Combination Agreement With TCGX Acquisition Corp.
October 28, 2026
October 28, 2026
PALO ALTO, California, Oct. 28 -- Cooley, a law firm, issued the following news release:
* * *
Cooley Advised TriGemX Bio on Business Combination Agreement with TCGX Acquisition Corp.
October 27, 2026
Cooley advised TriGemX Bio, a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, on its definitive business combination agreement with TCGX Acquisition Corp. (Nasdaq: TCGX), a special purpose . . .
* * *
Cooley Advised TriGemX Bio on Business Combination Agreement with TCGX Acquisition Corp.
October 27, 2026
Cooley advised TriGemX Bio, a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, on its definitive business combination agreement with TCGX Acquisition Corp. (Nasdaq: TCGX), a special purpose . . .